Hennig Arzneimittel &Kg

Hennig Arzneimittel is a fourth-generation, family-run German pharmaceutical company with a dual business model. Its core commercial focus is on generic prescription drugs, with a specialization in treatments for vertigo and sleep disorders, complemented by a growing portfolio of innovative, pharmacy-exclusive OTC products for conditions like head lice and warts. The company's second, significant revenue pillar is its established CDMO division, which offers end-to-end services from galenic development to packaging, specializing in modified-release solid dosage forms for pharmaceuticals, nutraceuticals, and medical devices. This combination of a niche-focused commercial portfolio and a service-based manufacturing arm provides diversified stability.

Specialized expertise in the galenic development and manufacturing of solid oral dosage forms, with a core focus on technologies for modified-release drug delivery (e.g., sustained-release/Retard tablets). The platform encompasses full-service capabilities from formulation development, scale-up, analytical testing, to commercial production and packaging for pharmaceuticals, nutraceuticals, and medical devices.

In generics, Hennig competes with global giants (Teva, Sandoz, Viatris) and European mid-sized players, differentiating via niche focus (vertigo) and modified-release expertise. In OTC, it competes with consumer health divisions of large pharma (Bayer, GSK) and specialized OTC companies, leveraging pharmacy-exclusive positioning. As a CDMO, it competes with other specialized European manufacturers for solid dosage forms, competing on technological capability, quality, and service flexibility.